PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients. MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion. RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041). CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.
PURPOSE: The aim of this study was to evaluate continuous vancomycin infusion (contV) in intensive care unit patients. MATERIALS AND METHODS: A retrospective study in 164 patients treated with contV was conducted. They were compared with 75 patients treated with intermittent vancomycin infusion. RESULTS: The median duration of vancomycin therapy in the contV group was 6 (5%-95% percentile range, 2-21) days. The median daily vancomycin dose in the contV group was 960 (526-1723) mg, resulting in a median serum vancomycin plateau concentration of 19.8 (9.8-29.4) mg/L (target: 15-25 mg/L). The contV administration regime was sufficient regarding achievement of the target serum vancomycin concentration. However, in the contV group, serum vancomycin levels were frequently in a subtherapeutic range on treatment days 1 (44%), 2 (29%), and 3 (23%). In the contV group, serum vancomycin concentration determinations per treatment day were performed significantly less often compared with the intermittent vancomycin infusion group (0.38 [0.15-0.75] vs 0.43 [0.22-1.00], P = .041). CONCLUSIONS: In medical intensive care unit patients, contV is sufficient to achieve target serum vancomycin concentrations. Because contV frequently resulted in subtherapeutic drug levels on the first days of therapy, a higher loading or starting dose might be necessary.
Authors: Erik M van Maarseveen; Annemien Bouma; Daniel J Touw; Cees Neef; Arthur R H van Zanten Journal: Eur J Clin Pharmacol Date: 2014-08-30 Impact factor: 2.953
Authors: Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: V Bakke; H Sporsem; E Von der Lippe; I Nordøy; Y Lao; H C Nyrerød; L Sandvik; K R Hårvig; J F Bugge; E Helset Journal: Acta Anaesthesiol Scand Date: 2017-04-25 Impact factor: 2.105
Authors: Carolina Hikari Yamada; João Paulo Telles; Dayana Dos Santos Oliveira; Juliette Cieslinski; Victoria Stadler Tasca Ribeiro; Juliano Gasparetto; Felipe Francisco Tuon Journal: Braz J Infect Dis Date: 2020-08-05 Impact factor: 3.257